The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.
Charlotte Rose Lemech
No relevant relationships to disclose
Antoinette Fontela
No relevant relationships to disclose
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Melvin T.M. Chin
No relevant relationships to disclose
Sandra Li
No relevant relationships to disclose
Winston S. Liauw
No relevant relationships to disclose
David Thomas
No relevant relationships to disclose
Paul L. De Souza
No relevant relationships to disclose